Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to Strong-Buy at StockNews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Wednesday.

A number of other equities analysts have also commented on the company. Argus boosted their price objective on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Royal Bank of Canada boosted their price objective on Regeneron Pharmaceuticals from $1,252.00 to $1,260.00 and gave the stock an “outperform” rating in a research note on Friday, October 4th. Piper Sandler boosted their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research note on Friday, August 23rd. Finally, Barclays boosted their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $1,119.00.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded up $6.93 during trading on Wednesday, hitting $1,012.19. 598,061 shares of the stock were exchanged, compared to its average volume of 493,713. Regeneron Pharmaceuticals has a 1-year low of $769.19 and a 1-year high of $1,211.20. The company has a market capitalization of $111.53 billion, a price-to-earnings ratio of 29.90, a price-to-earnings-growth ratio of 3.55 and a beta of 0.12. The company’s fifty day simple moving average is $1,122.57 and its 200-day simple moving average is $1,038.45. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. Regeneron Pharmaceuticals’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $8.79 EPS. Sell-side analysts expect that Regeneron Pharmaceuticals will post 37.8 EPS for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at $4,498,280. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph J. Larosa sold 1,866 shares of the business’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the completion of the transaction, the executive vice president now directly owns 37,937 shares in the company, valued at $41,311,496.15. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 8,033 shares of company stock worth $9,399,345 in the last 90 days. Insiders own 7.48% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. B & T Capital Management DBA Alpha Capital Management acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $1,298,000. UMB Bank n.a. raised its stake in shares of Regeneron Pharmaceuticals by 1.1% in the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after purchasing an additional 10 shares during the last quarter. Adirondack Trust Co. raised its stake in shares of Regeneron Pharmaceuticals by 2.4% in the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after purchasing an additional 10 shares during the last quarter. Wedmont Private Capital raised its stake in shares of Regeneron Pharmaceuticals by 4.5% in the third quarter. Wedmont Private Capital now owns 1,496 shares of the biopharmaceutical company’s stock worth $1,490,000 after purchasing an additional 65 shares during the last quarter. Finally, CWM LLC raised its stake in shares of Regeneron Pharmaceuticals by 1.1% in the third quarter. CWM LLC now owns 2,272 shares of the biopharmaceutical company’s stock worth $2,389,000 after purchasing an additional 25 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.